Globus Medical Inc (NYSE:GMED) – Research analysts at William Blair boosted their Q4 2018 earnings per share estimates for shares of Globus Medical in a report issued on Tuesday. William Blair analyst K. Krum now forecasts that the medical device company will post earnings per share of $0.39 for the quarter, up from their previous forecast of $0.37.

GMED has been the topic of several other research reports. Barclays reduced their price objective on shares of Globus Medical from $28.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, October 19th. ValuEngine lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. BidaskClub raised shares of Globus Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Globus Medical in a research note on Thursday, October 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.57.

Globus Medical (NYSE GMED) opened at $43.66 on Friday. Globus Medical has a one year low of $25.67 and a one year high of $46.51. The firm has a market cap of $4,207.78, a P/E ratio of 34.93, a P/E/G ratio of 2.92 and a beta of 0.56.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Wednesday, November 8th. The medical device company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The business had revenue of $151.74 million for the quarter, compared to analyst estimates of $150.73 million. During the same quarter last year, the firm earned $0.29 EPS. Globus Medical’s quarterly revenue was up 11.9% compared to the same quarter last year.

In other Globus Medical news, President Anthony L. Williams sold 15,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $38.30, for a total value of $574,500.00. Following the transaction, the president now owns 15,000 shares of the company’s stock, valued at $574,500. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider A Brett Murphy sold 51,449 shares of Globus Medical stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the completion of the transaction, the insider now directly owns 49,768 shares in the company, valued at approximately $1,741,880. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,908 shares of company stock worth $4,747,975. Insiders own 28.21% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in GMED. Sei Investments Co. lifted its stake in Globus Medical by 18.9% in the second quarter. Sei Investments Co. now owns 3,165 shares of the medical device company’s stock valued at $105,000 after buying an additional 503 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Globus Medical by 10.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 323,853 shares of the medical device company’s stock valued at $10,736,000 after buying an additional 31,452 shares in the last quarter. First Trust Advisors LP lifted its stake in Globus Medical by 279.3% in the second quarter. First Trust Advisors LP now owns 29,335 shares of the medical device company’s stock valued at $972,000 after buying an additional 21,602 shares in the last quarter. Legal & General Group Plc lifted its stake in Globus Medical by 19.9% in the second quarter. Legal & General Group Plc now owns 55,704 shares of the medical device company’s stock valued at $1,848,000 after buying an additional 9,229 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Globus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 5,398 shares of the medical device company’s stock valued at $179,000 after buying an additional 808 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/research-analysts-issue-forecasts-for-globus-medical-incs-q4-2018-earnings-gmed/1806710.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with Analyst Ratings Network's FREE daily email newsletter.